305 related articles for article (PubMed ID: 38449562)
1. Immunotherapy for the treatment of biliary tract cancer: an evolving landscape.
Wilbur HC; Azad NS
Ther Adv Med Oncol; 2024; 16():17588359241235799. PubMed ID: 38449562
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies.
Lo JH; Agarwal R; Goff LW; Heumann TR
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444422
[TBL] [Abstract][Full Text] [Related]
3. New Era of Immune-Based Therapy in Intrahepatic Cholangiocarcinoma.
Kawamura E; Matsubara T; Kawada N
Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568808
[TBL] [Abstract][Full Text] [Related]
4. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.
Athauda A; Fong C; Lau DK; Javle M; Abou-Alfa GK; Morizane C; Steward K; Chau I
Cancer Treat Rev; 2020 Jun; 86():101998. PubMed ID: 32203843
[TBL] [Abstract][Full Text] [Related]
5. Changing Landscape of Systemic Therapy in Biliary Tract Cancer.
Woods E; Le D; Jakka BK; Manne A
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565266
[TBL] [Abstract][Full Text] [Related]
6. Current and emerging immunotherapeutic approaches for biliary tract cancers.
Yuan ZG; Zeng TM; Tao CJ
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807
[TBL] [Abstract][Full Text] [Related]
7. Systemic treatment options for advanced biliary tract carcinoma.
Xie C; McGrath NA; Monge Bonilla C; Fu J
J Gastroenterol; 2020 Oct; 55(10):944-957. PubMed ID: 32748173
[TBL] [Abstract][Full Text] [Related]
8. Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective.
Neuzillet C; Artru P; Assenat E; Edeline J; Adhoute X; Sabourin JC; Turpin A; Coriat R; Malka D
Target Oncol; 2023 Jan; 18(1):51-76. PubMed ID: 36745342
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the Therapeutic Potential of Durvalumab in Adults with Locally Advanced or Metastatic Biliary Tract Cancer: Evidence to Date.
Storandt MH; Jin Z; Mahipal A
Onco Targets Ther; 2024; 17():383-394. PubMed ID: 38774819
[TBL] [Abstract][Full Text] [Related]
10. Recent advances of immunotherapy for biliary tract cancer.
Rizzo A; Ricci AD; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):527-536. PubMed ID: 33215952
[No Abstract] [Full Text] [Related]
11. Current Role and Future Perspectives of Immunotherapy and Circulating Factors in Treatment of Biliary Tract Cancers.
Conci S; Catalano G; Roman D; Zecchetto C; Lucin E; De Bellis M; Tripepi M; Guglielmi A; Milella M; Ruzzenente A
Int J Med Sci; 2023; 20(7):858-869. PubMed ID: 37324191
[TBL] [Abstract][Full Text] [Related]
12. Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer.
Oh DY; He AR; Qin S; Chen LT; Okusaka T; Vogel A; Kim JW; Suksombooncharoen T; Lee MA; Kitano M; Burris H; Bouattour M; Tanasanvimon S; McNamara MG; Zaucha R; Avallone A; Tan B; Cundom J; Lee CK; Takahashi H; Ikeda M; Chen JS; Wang J; Makowsky M; Rokutanda N; Żotkiewicz M; Kurland JF; Cohen G; Valle JW
Future Oncol; 2023 Nov; 19(34):2277-2289. PubMed ID: 37746835
[TBL] [Abstract][Full Text] [Related]
13. Current progress in systemic therapy for biliary tract cancers.
Sutherland M; Ahmed O; Zaidi A; Ahmed S
J Hepatobiliary Pancreat Sci; 2022 Oct; 29(10):1094-1107. PubMed ID: 33735541
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives.
Filippi R; Lombardi P; Quarà V; Fenocchio E; Aimar G; Milanesio M; Leone F; Aglietta M
Expert Opin Pharmacother; 2019 Dec; 20(17):2121-2137. PubMed ID: 31550186
[No Abstract] [Full Text] [Related]
15. Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers.
Kang S; El-Rayes BF; Akce M
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406520
[TBL] [Abstract][Full Text] [Related]
16. Paradigm shift of chemotherapy and systemic treatment for biliary tract cancer.
Leowattana W; Leowattana T; Leowattana P
World J Gastrointest Oncol; 2023 Jun; 15(6):959-972. PubMed ID: 37389105
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
Front Immunol; 2022; 13():946861. PubMed ID: 35967452
[TBL] [Abstract][Full Text] [Related]
18. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
Mody K; Jain P; El-Refai SM; Azad NS; Zabransky DJ; Baretti M; Shroff RT; Kelley RK; El-Khouiery AB; Hockenberry AJ; Lau D; Lesinski GB; Yarchoan M
JCO Precis Oncol; 2022 Jun; 6():e2100510. PubMed ID: 35675577
[TBL] [Abstract][Full Text] [Related]
19. Current options and future directions of systemic therapy for advanced biliary tract cancer.
Prete MG; Cammarota A; D'Alessio A; Zanuso V; Rimassa L
Explor Target Antitumor Ther; 2021; 2(5):416-433. PubMed ID: 36045701
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapies in advanced biliary tract cancers-a narrative review.
LaPelusa M; Heumann T; Goff L; Agarwal R
Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
